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Serum CA125 Concentration has Inverse Correlation with 
Metabolic Syndrome
Serum carbohydrate antigen 125 (CA-125) is a marker of ovarian cancer and obesity that is 
related with an increased risk of ovarian cancer. Obesity is a key factor of metabolic 
syndrome. We evaluated the relationship between CA-125 concentration and metabolic 
syndrome. The data from subjects who had any cancer and chronic infection were 
excluded. The data of 12,196 healthy Korean women were analyzed. After CA-125 
concentration was divided by quartiles, the prevalence of metabolic syndrome and its 
components were compared. The lowest quartile of CA-125 compared with the highest 
quartile showed elevated values of most of metabolic parameters. In addition, as the 
quartile of CA-125 increased, metabolic derangement decreased. Increased numbers of 
metabolic syndrome components showed an inverse association with CA-125 levels 
(P < 0.001). The odds ratio (OR) for the lowest CA-125 quartile vs the highest CA-125 
quartile significantly increased in the presence of metabolic syndrome (OR = 1.202, 95% 
Confidence Interval [CI] 1.013–1.423), elevated triglyceride (OR = 1.381, 95% CI 1.167–
1.633), and low high-density lipoprotein cholesterol (OR = 1.168, 95% CI 1.039–1.312). 
The presence of metabolic syndrome, elevated triglyceride, or low high-density lipoprotein 
cholesterol negatively correlates with CA-125 concentration. 
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INTRODUCTION
Carbohydrate antigen 125 (cancer antigen 125, CA-125) is a high 
molecular weight glycoprotein that is a serum biomarker or tu-
mor antigen. CA-125 is elevated in the blood of some patients 
with specific types of cancers and is increased in some women 
with early stage ovarian cancer (1, 2). Therefore, it is used glob-
ally as a serological marker of malignant tumors. In post-meno-
pausal women without ovarian cancer, the CA-125 level is in-
fluenced by a number of factors, including race/ethnicity, age, 
hysterectomy, smoking, and obesity (3). 
  Metabolic syndrome is a combination of several metabolic 
and physiological abnormalities in the same individual, includ-
ing obesity, insulin resistance, glucose intolerance, hyperten-
sion, and dyslipidemia, and is associated with high morbidity 
and mortality (4, 5). Metabolic syndrome has also been identi-
fied as a causal risk factor for cardiovascular disease and several 
forms of cancer, such as cancers of the breast, pancreas, and co-
lon (6-8). Obesity is the one of the most important causes of met-
abolic syndrome, which also can affect many gynecologic can-
cers, in particular ovarian and endometrial cancers (9). Howev-
er, although obesity can increase the incidence of cancer, a high 
body mass index (BMI) does not seem to adversely influence 
the prognosis in patients with some gynecological malignan-
cies (10). 
  There is no previous report for the relationship between se-
rum CA-125 and metabolic syndrome. The aim of this cross-sec-
tional study was to evaluate the relationship of serum CA-125 
levels with metabolic syndrome in healthy Korean women. 
MATERIALS AND METHODS
From January 2007 to May 2009, the data of 13,845 Korean wom-
en aged 20-83 years who visited the Health Promotion Center, 
Ajou University Hospital, Suwon, Gyeonggi-do, Republic of Ko-
rea, were included in the study. Medical history, demographics, 
anthropometric, and laboratory data were collected. Data on 
cigarette smoking were collected by a self-reported question-
naire. Subjects who, at the time of the survey, had ceased smok-
ing for  ≤ 1 month or  > 1 month were considered to be, respec-
tively, current and former smokers. Those without a smoking 
history were considered to be never smokers. But, in the data, 
there were a small number of women who were current smok-
ers (3.65%). Of the initial 13,845 subjects, 1,649 women were ex-
cluded because of absent data for any component of metabolic 
syndrome, serum CA-125 levels, or smoking history. Subjects Joo N-S, et al.  •  Serum CA125 and Metabolic Syndrome
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with prior diagnosis of any cancer and chronic infections such 
as rheumatoid arthritis, viral hepatitis, and chronic liver diseas-
es were excluded. A total of 12,196 healthy Korean women were 
included in the final analyses. 
  CA-125 was determined with an electrochemoiluminescence 
immunoassay (Roche Modular Analytics E170; Roche Diagnos-
tics, Mannheim, Germany). Blood pressure (BP) was measured 
using a standard mercury manometer with the participant in a 
sitting position for 5 min prior to measurement; the average of 
two measurements was recorded. Circumferential measure-
ments of the waist at the umbilicus were performed with the 
patients in a standing position. Fasting blood specimens were 
used for measuring lipids, glucose, and CA-125. Metabolic syn-
drome was defined as three or more of the following criteria, 
according to the National Cholesterol Education Program Third 
Adult Treatment Panel guidelines (NCEP ATP III) (11): waist cir-
cumference (WC)  ≥ 102 cm for males and  ≥ 88 cm for females, 
triglyceride (TG) level  ≥ 150 mg/dL, high-density lipoprotein 
cholesterol (HDLC)  < 50 mg/dL, BP  ≥ 130/85 mmHg or the use 
of BP medications, and fasting glucose level  ≥ 110 mg/dL. Ab-
dominal girth cut-off to determine WC was defined according 
to the NCEP guidelines specified for Asia ( ≥ 90 cm for males and 
≥ 85 cm for females). Subjects were grouped by smoking status, 
the sum of individual metabolic components (0-5), and the pres-
ence or absence of metabolic syndrome (yes or no). BMI was 
calculated as weight (kg) divided by height squared (m
2).
Statistics
ANOVA was used to compare subjects’ characteristics according 
to serum CA-125 quartiles such as metabolic syndrome com-
ponents and smoking status. ANOVA trend analysis using poly-
nomial contrasts was adapted to perform tests for trend. Multi-
variate logistic and linear regression analyses were performed to 
examine whether clinical parameters and smoking status would 
significantly contribute to changes in serum CA-125 levels. Re-
sults of group data and CA-125 levels are expressed as mean ±  
standard deviation (SD). All statistical analyses were performed 
using SPSS 13.0 software (SPSS, Chicago, IL, USA).  P values < 0.05 
were considered statistically significant. 
Ethics statement
The institutional review board of Ajou University Hospital ap-
proved this study conduction (AJIRB-MED-OBS-10-415). The 
board waived informed consent from subjects.
RESULTS
The characteristics of 12,196 subjects according to the quartiles 
of CA-125 are summarized in Table 1. The overall proportion of 
metabolic syndrome was 11.5%. Interestingly, most of the met-
abolic markers in the lowest quartile (Q1) of CA-125 showed 
higher values compared with the highest quartile (Q4). Num-
bers of current cigarette smokers were not so high because the 
data were from women. We compared the prevalence of abnor-
mal metabolic syndrome parameters such as elevated WC, ele-
vated TG, elevated BP, elevated fasting blood sugar and decreased 
HDLC according to the quartile of CA-125 concentration. Fig. 1 
presents the patterns of the abnormal metabolic parameters. 
The prevalence of metabolic syndrome and its all components 
showed a significant decrease according to the quartile of serum 
CA125 concentration increase (P < 0.05). We also calculated the 
mean CA-125 concentration by the numbers of metabolic syn-
drome. The mean concentration of CA-125 showed the trend  
of decrease as the numbers of metabolic syndrome increased. 
Especially, the mean concentration of CA-125 significantly de-
creased above the two parameters of metabolic syndrome com-
ponents (Fig. 2). We conducted logistic regression analysis of 
metabolic syndrome and its components as independent vari-
Table 1. Baseline characteristics of study subjects according to the quartile of serum CA125 concentration
Variables*
Q1 (n = 3,068)  
( < 11.20 ng/mL)
†
Q2 (n = 3,006)  
(11.20-14.89 ng/mL)
†
Q3 (n = 3,059)  
(14.90-20.60 ng/mL)
†
Q4 (n = 3,063)  
( ≥ 20.70 ng/mL)
†
Age (yr)   49.61 ± 11.58   45.88 ± 11.21   43.79 ± 10.33 41.49 ± 8.86
BMI (kg/m
2)  23.23 ± 3.08 22.94 ± 3.13 22.74 ± 3.10 22.48 ± 3.10
WC (cm)  81.95 ± 8.44 80.84 ± 8.30 80.41 ± 7.97 79.61 ± 7.98
TG (mg/dL)   93.36 ± 60.50   90.77 ± 62.24   89.84 ± 68.32   87.21 ± 58.01
HDLC (mg/dL)     57.71 ± 13.11   57.98 ± 13.31   58.26 ± 13.01   57.80 ± 12.96
SBP (mm Hg)  118.28 ± 15.83 115.94 ± 15.66 114.99 ± 15.26 113.70 ± 14.55
DBP (mm Hg)   74.78 ± 10.95   73.45 ± 10.78   72.99 ± 10.56   72.66 ± 10.71
FBS (mg/dL)   93.69 ± 16.92   93.40 ± 19.42   92.41 ± 17.04   91.62 ± 16.94
TC (mg/dL)  186.59 ± 34.50 183.67 ± 34.27 182.99 ± 34.54 181.32 ± 32.50
Smoking status
   Non (n, %)
   Former (n, %)
   Current (n, %)
 
2,863 (93.3)
   59 (1.9)
 146 (4.8)
 
2,846 (94.7)
   56 (1.9)
 104 (3.5)
 
2,908 (95.1)
   57 (1.9)
   94 (3.1)
 
2,890 (94.3)
   72 (2.4)
 102 (3.3)
*P < 0.05; All values showed statistical significance in the comparisons of variables according to the quartile of serum CA125 concentration by ANOVA test. 
†Data are present-
ed as CA125 range. Data are shown as mean ± SD. BMI, body mass index; WC, waist circumference; TG, triglyceride; HDLC, high-density lipoprotein cholesterol; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar, TC; total cholesterol; Non, non-smoker; Former, former smoker; Current, current smoker.Joo N-S, et al.  •  Serum CA125 and Metabolic Syndrome
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ables and CA-125 quartiles as dependent variables. As the con-
centration of CA-125 decreased as the quartile increased, we 
regarded the highest quartile as the reference group. The odds 
ratios (ORs) for the lowest CA-125 quartile compared with the 
highest CA-125 quartile were significant in the presence of met-
abolic syndrome and elevated TG and low HDLC before and 
after age-adjustment (Table 2). 
 
DISCUSSION
In this cross-sectional observational study, an inverse correla-
tion was evident between serum CA-125 concentration and met-
abolic syndrome, and its components such as TG and HDLC. 
The presence of metabolic syndrome, elevated TG, or low HDLC 
negatively correlated with CA-125 concentration. 
  Over the past two decades, the prevalence of metabolic syn-
drome has sharply increased worldwide, and is associated with 
the global epidemic of obesity and diabetes (5, 12, 13). Meta-
bolic syndrome is associated with the increased risks of cardio-
vascular disease and various cancers (6, 7, 14). Obesity is a key 
factor of metabolic syndrome and it is a risk factor for ovarian 
cancer because of its relationship to sex steroid hormones (15). 
Table 2. Logistic regression analysis of the metabolic syndrome and its components as independent variables and CA125 quartile as a dependent variable
Clinical components 
Odds Ratio (95% CI)
Q4 Q3 Q2 Q1
MS
   Model 1
   Model 2
1
1
  
1.210 (1.025-1.428)
1.067 (0.895-1.273)
  
1.549 (1.321-1.818)
1.020 (0.859-1.210)
  
 1.874 (1.605-2.188)
1.201* (1.013-1.423)
Increased WC
   Model 1
   Model 2
1
1
 
1.224 (1.094-1.370)
1.062 (0.944-1.195)
 
1.394 (1.247-1.559)
1.060 (0.942-1.192)
 
 1.760 (1.578-1.963)
 1.060 (0.942-1.194)
Elevated TG
   Model 1
   Model 2
1
1
 
1.087 (0.924-1.278)
1.098 (0.929-1.297)
 
1.205 (1.027-1.413)
1.151 (0.975-1.359)
 
 1.291 (1.104-1.511)
1.381* (1.167-1.633)
Low HDLC
   Model 1
   Model 2
1
1
 
0.933 (0.833-1.044)
1.135 (1.013-1.273)
  
1.025 (0.916-1.146)
1.089 (0.971-1.221)
  
 1.054 (0.943-1.178)
1.168* (1.039-1.312)
Elevated BP
   Model 1
   Model 2
 
1
1
 
1.214 (1.073-1.374)
1.035 (0.905-1.185)
 
1.459 (1.292-1.647)
1.043 (0.913-1.192)
 
 1.973 (1.754-2.219)
 1.055 (0.925-1.205)
IFG
   Model 1
   Model 2
 
1
1
 
1.129 (0.981-1.298)
1.067 (0.922-1.235)
 
1.311 (1.143-1.504)
1.070 (0.926-1.237)
 
 1.593 (1.395-1.820)
 1.136 (0.984-1.312)
*P < 0.05. MS, metabolic syndrome; BMI, body mass index; WC, waist circumference; TG, triglyceride; HDLC, high-density lipoprotein cholesterol; BP, blood pressure; IFG, im-
paired fasting glucose; Q2, 2nd quartile; Q3, 3rd quartile; Q4, 4th quartile. CI, confidence interval; Reference group, no metabolic syndrome and normal metabolic components. 
Model 1; before adjustment, Model 2; after adjustment for age.
Fig. 2. The relationship between CA125 level and the sum of metabolic syndrome 
components. Vertical bars indicate 95% confidence interval. Circles denote the mean. 
Lower and upper bars indicate 95% confidence interval (P trend < 0.001).  
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Fig. 1. Prevalence of metabolic syndrome and its components according to the quar-
tile of serum CA125 concentration. Prevalence of metabolic syndrome and its all com-
ponents showed a significant decrease according to the quartile of serum CA125 
concentration (P < 0.05). WC, waist circumference; HDLC, high-density lipoprotein 
cholesterol; BP, blood pressure; IFG, impaired fasting glucose. Q1; 1st quartile; Q2, 
2nd quartile; Q3, 3rd quartile; Q4, 4th quartile.Joo N-S, et al.  •  Serum CA125 and Metabolic Syndrome
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There have been many studies on obesity and ovarian cancer. 
One study evaluated the impact of obesity on ovarian cancer 
risk using BMI as the measure of obesity (16). Another study 
using the new guidelines and a larger sample confirmed the as-
sociation between obesity and increased risk for ovarian cancer 
at 70% (17). Obesity was associated with clear cell cancers, where 
a 2-fold increased risk was observed (OR 2.2, 95% confidence 
interval [CI] 1.2-4.1) (18). There was no association with BMI at 
age 20, or weight gain for any of the histological subtypes of ovar-
ian cancer. These results add to the current evidence that obesi-
ty increases a woman’s risk of developing distinct histological 
subtypes of ovarian cancer (19). Increasing BMI has been asso-
ciated with an increased incidence of ovarian cancer (relative 
risk = 1.14, 95% CI 1.03-1.27) (20). In a meta-analysis, 24 of 28 
studies reported a positive association between obesity and ovar-
ian cancer (9). Overexpression of some lipid metabolic enzymes 
is also found in ovarian cancer (21). 
  A search of the literature revealed over 10,000 articles on the 
ovarian cancer. Thousands of scientific studies have reported 
on metabolic syndrome. It is impossible to review all these pa-
pers. However, in stark contrast, little data has been published 
concerning the association of the concentration of CA-125 and 
metabolic syndrome. As described above, CA-125 is a marker 
of ovarian cancer and obesity is both related with the increase 
of ovarian cancer risk and is a key factor of metabolic syndrome. 
By simple assumption, CA-125 would be expected to have a pos-
itive relationship with obesity and metabolic syndrome. How-
ever, presently, CA-125 was inversely correlated with the pres-
ence of metabolic syndrome and the numbers of metabolic syn-
drome components. We are unsure why this pattern was appar-
ent. One possible mechanism is that subjects with a greater BMI 
have larger plasma volumes, which could decrease the serum 
concentrations of soluble tumor markers-a phenomenon known 
as hemodilution (22). In addition, increased BMI has a reported 
negative association with CA-125 concentration (3). In the latter 
study, the mean concentration of CA-125 in the obese group of 
patients decreased minimally compared to the normal and over-
weight groups. Furthermore, the OR of obese patients having an 
elevated CA-125 was significantly decreased compared to the 
normal weight group. Therefore, a serum concentration of CA-
125 was negative correlated with obesity, which was also corre-
lated with metabolic syndrome. Consequently, women who have 
metabolic syndrome may have a low level of serum CA-125. 
  CA-125 is best-known as a marker for ovarian cancer, but it 
may also elevated in other benign medical conditions such as 
endometrial, fallopian tube, lung, breast and gastrointestinal 
tract problems (1). It also tends to be elevated in the presence of 
any inflammation condition in the abdominal area, be it cancer-
ous or benign (23). However, with the current clinical approach, 
it is difficult to clarify the mechanism of the negative association 
between CA-125 and metabolic syndrome, because there have 
not been any clinical or experimental reports on the relationship 
between CA-125 and metabolic syndrome. Thus, it is necessary 
to investigate the relationship between CA-125 and metabolic 
syndrome at the cellular and molecular levels, or by a prospec-
tive intervention study to evaluate the change of CA-125 accord-
ing to the changes of BMI or improvement of metabolic syndrome. 
  There are some limitations with this study. First, because the 
study was cross-sectional, we could not determine whether there 
was a causal or resultant relationship between the individual 
and the combined components of metabolic syndrome and the 
elevation of serum CA-125. Second, it is not clear whether the 
analysis of this restricted patient group introduced a selection 
bias, and these findings may or may not reflect the situation in 
the overall population. Third, we analyzed the data of all ages in 
the health promotion center not of high risk or postmenopaus-
al women. Finally, we could not adjust for all possible confound-
ing factors. Nevertheless, our study is the first report on the re-
lationship of the CA-125 and metabolic syndrome and its param-
eters. 
  In conclusion, the presence of metabolic syndrome or elevat-
ed TG or low HDLC is negatively correlated with CA-125 con-
centration in this cross-sectional observational study. 
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